Selected Publications

Ramiro S, Gaillez C, Kiltz U, Gensler LS, Pisal C, Braun J, Ogdie A.: No major effect of age (< 40 vs. ≥ 40 years) on response to secukinumab in patients with axSpA: a post hoc analysis of six phase 3 trials. Arthritis Res Ther Apr 2026.

Romich E, Ogdie A, Stephens-Shields A, Merkel PA, Assassi S, Bernstein EJ, Bujor A, Castelino FV, Chung L, Evnin LB, Frech TM, Gordon JK, Griffith M, Hant FN, Harding ML, Hummers LK, Khanna D, Lakin KS, Lebiedz-Odrobina DJ, Luo Y, Makol A, Mayes MD, McMahan ZH, Molitor J, Moore DF, Paik J, Richardson C, Skaug B, Shah AA, Shah A, Steen V, VanBuren JM, Volkmann ER, Zahn C, Sandorfi N; CONQUER Investigators.: Discordance between patient and physician global assessments in early systemic sclerosis. Arthritis Care Res (Hoboken) Apr 2026.

Baker JF, Wysham KD, Quinones M, England BR, Jin K, Olave M, Wetzel S, Gillcrist RL, Lavery C, Keller N, Kramer B, Ateh B, Brubeck H, White DK, Ogdie A, Xiao R, Neogi T, Scanzello CR.: Behavioral Incentives for Exercise and Intra-Articular Corticosteroids for Knee Osteoarthritis: Results from a Factorially Designed Pragmatic Randomized Clinical Trial. Arthritis Rheumatol Apr 2026.

Nikiphorou E, Ogdie A, Twigg D, Quiñones E, Ling YL, Cappelleri JC, Sanchez-Riera L, Masri KR, Hughes M, Massey N.: Treatment satisfaction, disease severity, and health-care use in patients with axial spondyloarthritis in the United States and Europe. Rheumatology (Oxford) 65: keag106, Mar 2026.

Merola JF, Mease P, Kivitz A, Sattar N, Coates LC, Aletaha D, Kartman CE, Fischer P, Sun L, Martínez-Osuna P, Kronbergs A, Prajapati P, Cardoso A, Genovese MC, Ogdie A.: Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial. Arthritis Rheumatol Mar 2026.

Ogdie A, Middaugh N, Marchese M, Walsh JA, Bello N, Ngantcha M, Kronbergs A, Grace EL, Mease PJ.: Cycling to TNFi vs. Switching to IL-17Ai Among Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Real-World CorEvitas PsA/SpA Registry Data. Adv Ther Mar 2026.

Ogdie A, Merola JF, Mease PJ, Ritchlin CT, Scher JU, Lafferty KP, Chan D, Chakravarty SD, Langholff W, Wang Y, Shao J, Krol Y, Gottlieb AB.: Efficacy and Safety of Guselkumab in Participants with Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of the Phase 3, Randomized, Placebo-Controlled SOLSTICE Study. Arthritis Rheumatol Feb 2026.

Mease P, Ye X, Saffore CD, Parikh B, Ciecinski S, Blachley T, Eliot M, Middaugh N, Ogdie A.: Quantifying Disease Activity Despite Treatment with Tumor Necrosis Factor Inhibitors Among Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Real-World Results from the PPD CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. Rheumatol Ther 2026.

Leung YY, Haugegaard T, Annfeldt TK, Holland R, Strand V, Mease P, Tugwell P, Wells GA, Shea BJ, Mathew AJ, Goel N, Lindsay C, Ogdie A, Orbai AM, Coates LC, Gladman DD, Tillett W, Chau J, Christensen R.: Determining the best discriminatory physical functioning outcome measurement instrument for psoriatic arthritis trials: A meta-epidemiological study. Semin Arthritis Rheum 2026.

Gladman DD, Eder L, Selmi C, Mease PJ, Ogdie A, Lozenski K, Adamson E, Sharaf M, Rampakakis E, Pina Vegas L, Coates LC.: Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials. Rheumatol Ther Dec 2025.